



**VASCULAR HEALTH**  
CLINICS

---

## **VASCULAR SURGERY: AAA, CAROTID DISEASE AND PERIPHERAL ARTERIAL DISEASE (PAD)**

**Dr Omar P. Haqqani, MD**  
**Chief, Vascular and Endovascular Surgery**  
**Associate Professor of Surgery, Central Michigan University**



**Author does not have any disclosures**





## ABDOMINAL AORTIC ANEURYSMS

# ABDOMINAL AORTIC ANEURYSMS




VASCULAR HEALTH  
CLINICS



# ABDOMINAL AORTIC ANEURYSMS



## Normal Aortic Anatomy




# ABDOMINAL AORTIC ANEURYSMS




VASCULAR HEALTH  
CLINICS


**Ascending Thoracic  
Aortic Aneurysm (TAA)**



**Descending Thoracic  
Aortic Aneurysm (TAA)**



**Abdominal  
Aortic Aneurysm (AAA)**



**Fusiform  
Aneurysm**



**Saccular  
Aneurysm**



## Types of Abdominal Aortic Aneurysms

**Infrarenal**  
Below renal arteries

**80%**

Renal arteries

Common iliac arteries

Internal iliac (hypogastric) arteries


External iliac arteries

**Juxtarenal**  
Below and adjacent to renal arteries


**20%**


**Suprarenal**  
At or above level of renal arteries and below superior mesenteric artery

Superior mesenteric artery












- **50% of all patients die of ruptured AAA before reaching the hospital**
- **30-40% die who reached the hospital**
- **Overall 80-90% mortality in ruptured AAA**

- **Infrarenal aorta: 1.8-2.2 cm in diameter**
- **Aneurysm defined as 2X normal diameter**
- **Growth rate 4.5 cm AAA (0.4 cm/yr, 10%/yr)**
- **Peripheral aneurysms in 3.5% (pop > femoral)**

- Male gender (6X > females)
- Smoking (5X nonsmokers)
- Caucasian (2.5X > African American)
- Family History (1.9X)
- Age (1.7X per 7 years)
- CAD (1.5X)
- Hypercholesterolemia (1.4X)
- COPD (1.2X)

# LAPLACE LAW



# AORTIC ANEURYSM FACTS



- Rationale for repair is prevention of rupture!
- Laplace's Law
- Risk of Rupture

Size (cm)	Annual Rupture Risk
<4.0	0.3%
4.0-4.9	1.5%
5.0-5.9	6.5%
6.5	20%
7.5	35%

# FACTORS ASSOCIATED WITH RUPTURE

---



VASCULAR HEALTH  
CLINICS

- Female gender (4.5X > Male)
- Smoking
- COPD
- Family History
- Hypertension
- Connective Tissue Disease (Marfans, Ehlers-Danlos)





## Society of Vascular Surgery, Medicare Screening

- Any Male who has smoked (65-75 yo)
- Any Male or Female with a family history of AAA
- Eliminates referral requirement as part of the Welcome to Medicare Physician Exam
- Eliminates the one-year time limit for all beneficiaries who are at risk for AAA
- This remains a one-time screening



- **Ultrasound**  
Used to diagnose and monitor AAA until aneurysm approaches size at which repair considered
  - **Computed Tomography**  
Used in preop assessment of AAA
- \* 3-4 mm difference between US and CT scan



1. Risk for AAA rupture without surgery
2. Operative risk of repair
3. Patient's life expectancy
4. Personal preference of patient

# 1. RISK OF RUPTURE

---

- **Size matters:**
  - **Aneurysm > 5cm 6-16% and > 7cm 33%**
- **Saccular aneurysm have higher rupture rate**
- **HTN, COPD, active smoking is independent predictors of rupture**
- **(+) Family Hx tend to rupture**
- **Expansion rate (> 5 mm over 6 months)**

## 2. OPERATIVE RISK OF REPAIR

---



- **Mortality after:**
  - **Elective open AAA ~ 5%**
  - **EVAR 1.7%**

### 3. PATIENTS LIFE EXPECTANCY

- Very difficult to assess due to patient's co-morbidities

Age	Life Expectancy after AAA repair (years)
60	13
70	10
80	6

## 4. PERSONAL PREFERENCES

---



- **Fear of AAA vs. Fear of surgery**
- **Anecdotal experiences of friends and family**



- **Smoking Cessation - Single most important modifiable risk factor**
- **Exercise Therapy - Evidence suggests may benefit small aneurysms**
- **Beta Blockers - May decrease the rate of expansion?**
- **ACE inhibitors - Evidence is mixed, however, implicated in less aneurysm rupture**





- **Doxycycline - Antibiotic activity against chlamydia species and suppresses expression of MMP**
- **Statins - associated with reduced aneurysm expansion rates. Decreases MMP-9 in aneurysm wall**


- **Asymptomatic**
- **Pulsatile mass**
- **Embolic phenomenon**
- **Compressive symptoms**
- **Acute onset of abdominal and back pain**
- **Hemorrhage and cardiovascular collapse**

- **>5.5 cm (5.0 cm)**
- **UK Small AAA Trial (Lancet 1998) & Aneurysm Detection and Management Trial (ADAM) (NEJM 2002)**
- **No difference in survival in 4.0-5.5 cm AAA when randomized to a strict surveillance vs immediate repair (follow-up 5 yrs)**
- **>60% of surveillance pts underwent repair**


# OPEN REPAIR AAA




VASCULAR HEALTH  
CLINICS



# OPEN REPAIR AAA



# EVAR REPAIR AAA



# EVAR REPAIR AAA

---




VASCULAR HEALTH  
CLINICS

# EVAR REPAIR AAA



VASCULAR HEALTH  
CLINICS








- Repair must outweigh the risk of rupture
- 30-day in-hospital mortality (3.8% to 8.2%) for elective open repair
- Same size criteria for elective open vs endovascular repair (EVAR)
- EVAR is associated with decreased morbidity and mortality in the early post-operative period

# OPEN VS EVAR

	EVAR I		DREAM	
	Open	EVAR	Open	EVAR
N	539	543	178	173
30 Day Mortality	4.7%	1.7%*	4.6%	1.2%*
Late All Cause Mortality	29% (4yr)	26% (4yr)	11% (2yr)	11% (2yr)
Late AAA Related Mortality	7% (4yr)	4% (4yr)	5%(2yr)*	2% (2yr)

\*  $p \leq 0.05$

# EVAR ELIGIBILITY REQUIREMENTS



A

- Short proximal neck
- Thrombus present in proximal landing zone
- Conical proximal neck
- $>120^\circ$  angulations of the proximal neck
- Critical inferior mesenteric artery
- Significant iliac occlusion
- Tortuosity of iliac vessels

# AAA DEVICE SELECTION




Copyright ©2005, 2000, 1995, 1989, 1976 by Elsevier, Inc.



Copyright ©2005, 2000, 1995, 1989, 1976 by Elsevier, Inc.

- **30 day mortality ranges 0-6% (1.2%)**
- **Reduced cardiac/pulmonary complications**
- **Contrast nephropathy**
- **Stent deployment issues**
- **Local trauma to access vessels**
- **Endoleaks**

# AORTIC ANEURYSM ENDOLEAKS





- **Successful exclusion and depressurization with shrinkage of the aneurysm sac**
- **CTA at 6 months and yearly**
- **Renal issues**
- **Patient compliance issues**



# ADVANTAGES



VASCULAR HEALTH  
CLINICS

## EVAR

**Lower perioperative mortality/morbidity**

**Shorter hospital stay**

**No ICU/Ventilator Care**

**Fewer transfusions**

**Strict followup**

**Shorter operative time**

**No ventral hernias**

## Open Repair


**Less frequent need for reintervention**

**No routine follow-up imaging**

**No endoleaks**

**? Lower Cost**

# RUPTURE PROTOCOL



# RUPTURED THORACIC ANEURYSM



VASCULAR HEALTH  
CLINICS

BAUDER, LAWRENCE L - [EVMS] Advanced Visualization

File Edit View Study Series Viewport Tools Study Note QC Window Help

BAUDER, LAWRENCE L #100022171  
#PatientStudies: 33  
Study #3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-06 06:20:52 -  
MMMC-MDLAND  
CT from SIEMENS

Score# 0.0 - 120s  
#1: 1 CT Images

APPLIED  
CONTRAST  
#4: 151 CT Images

APPLIED  
SAGITTAL  
#5: 155 Sag Images

APPLIED  
CORONAL  
#7: 319 CT Images

Patient Protocol  
#501: 1 CT Images

CT Chest w Contrast  
#3009: 2 CT Images

BAUDER, LAWRENCE L #100022171  
#PatientStudies: 33  
Study #3444487  
CT Chest w Contrast  
Acc#3444487  
2014-04-06 04:49:35 -  
MMMC-MDLAND  
CT from SIEMENS

Score# 0.0 - 120s  
#1: 1 CT Images

PATIENT: ID=100022171  
BAUDER, LAWRENCE L [M]  
1937-04-04 [77 years]

Ref=ROCKLAND, ERICH C  
Perf=ROCKLAND, ERICH C MD  
Read=Dr. Jeffrey, Herman

RESET

STUDY: ID=3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-06  
06:20:52 -  
Prior#1  
Read Series  
97%

SERIES: #6  
06:25:35  
SAGITTAL  
5.0mm / sp  
Contrast=APPLIED  
PH-MONOCHROME2  
691x512  
FOV: 24.6cm x 33.2cm

SLICE  
L: 31.89 mm  
W: 705 L: 135  
Slice 84 of 155  
Zoom=97%

# RUPTURED THORACIC ANEURYSM



VASCULAR HEALTH  
CLINICS

BAUDER, LAWRENCE L - [EVMS] Advanced Visualization

File Edit View Study Series Viewport Tools Study Note QC Window Help

BAUDER, LAWRENCE L #1017  
#PatientStudies: 33  
Study #3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-06 06:20:52 -  
MMMC-MDLAND  
CT from SIEMENS

BAUDER, LAWRENCE L #1017  
#PatientStudies: 33  
Study #3444487  
CT Chest w Contrast  
Acc#3444487  
2014-04-06 04:49:35 -  
MMMC-MDLAND  
CT from SIEMENS

PATIENT ID=1000022171  
BAUDER, LAWRENCE L [M]  
1937-04-04 [77 years]

Ref=ROCKLAND, ERICH C  
Perf=ROCKLAND, ERICH C MD  
Read=Dr. Jeffrey, Herman

STUDY: D=3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-06  
06:20:52 -  
Prior#1  
Read Series

SERIES: #4  
06:24:46  
Contrast: 2.0 B411  
2.0 INW / sp  
Contrast=APPLIED  
PH-MONOCHROME2  
512x512  
FOV: 32.5cm x 32.5cm

SLICE  
F: 169.50 mm  
W: 535 L:90  
Slice 114 of 151  
Zoom=130%

Start | SNSurgNet Organiz... | Omar P Haqqani: S... | BAUDER, LAWRENC... | 11:18 AM

# RUPTURED THORACIC ANEURYSM



VASCULAR HEALTH  
CLINICS

BAUDER, LAWRENCE L - [EVMS] Advanced Visualization

File Edit View Study Series Viewport Tools Study Note QC Window Help

Abd #5A-53 ZA Images Abd #5B-1 ZA Images Abd #6-23 ZA Images Abd #7A-25 ZA Images Abd #7B-1 ZA Images Abd #8-13 ZA Images Abd #9-24 ZA Images

BAUDER, LAWRENCE L #1000022171  
#PatientStudies: 30  
Study #3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-08 08:20:52 -  
MMMC-MCLAND  
CT from SIBRENS

Series: #5A  
11:26:46  
Abd  
1024x1024

PATIENT: ID=1000022171  
BAUDER, LAWRENCE L [M]  
1937-04-04 [077Y]  
Ref=HAQQANI, OMAR P  
Perf=HAQQANI, OMAR P  
Read=

STUDY: D=3444512  
ICXX Endovascular Repair Thoracic Aorta w/ Subclavian  
Acc#-3444512  
2014-04-08  
08:41:44 -  
Prior#2  
Multi-Frame Overlay Not Displayed  
65%

SLICE:  
R: 0.05 mm  
W: 4095 L: 2048  
Slice 27 of 53  
Zoom=65%  
Magnification=1.58

Start | SNSurgNet Organiz... | Omar P Haqqani: S... | BAUDER, LAWRENC... | BAUDER, LAWRENC... | 11:19 AM

# RUPTURED THORACIC ANEURYSM



VASCULAR HEALTH  
CLINICS

BAUDER, LAWRENCE L - [EVMS] Advanced Visualization

File Edit View Study Series Viewport Tools Study Note QC Window Help

Abd #54-537A Images Abd #55-17A Images Abd #6-337A Images Abd #7A-257A Images Abd #8B-17A Images Abd #9-137A Images Abd #9-247A Images

BAUDER, LAWRENCE L #1000022171  
#PatientStudies: 30  
Study #3444491  
CT Chest w Contrast  
Acc#3444491  
2014-04-08 08:20:52 -  
MMMC-MCLAND  
CT from SIBRENS

Series: #7A  
11:38:41  
Abd  
1024x1024

PATIENT: ID=1000022171  
BAUDER, LAWRENCE L [M]  
1937-04-04 [077Y]  
Ref=HAQQANI, OMAR P  
Perf=HAQQANI, OMAR P  
Read-


STUDY: D=3444512  
ICXX Endovascular Repair Thoracic Aorta w/ Subclavian  
Acc#-3444512  
2014-04-08  
08:41:44 -  
Prior#2  
Multi-Frame Overlay Not Displayed  
65%

SLICE:  
R: 0.03 mm  
W: 4095 L: 2048  
Slice 18 of 35  
Zoom=65%  
Magnification=1.58




## PERIPHERAL ARTERIAL DISEASE

# AGE DISTRIBUTION OF PAD





# IMPACT OF PAD ON MORTALITY





## Traditional Risk Factors

- Age
- Family history of CAD
- Cigarette smoking
- Hypertension
- Low HDL-C
- High total and LDL-C
- Diabetes mellitus
- Obesity

## Novel Risk Factors

- D-Dimer
- Lipoprotein (a)
- Serum amyloid A
- CMV, HSV, C. Pneumoniae
- Homocysteine
- Estrogen deficiency
- Plasma fibrinogen
- Factor VII
- C-reactive protein





## Autoregulation:

- dilation of peripheral arterioles distal to stenosis
- collateral pathway formation
- enhanced muscle metabolism/O<sub>2</sub> extraction

## Claudication and rest pain:

- accumulation of anaerobic metabolites lactic acid, adenosine monophosphate

## Lifestyle modification

- Smoking cessation
- Regular exercise training
- Diet

## Pharmacological treatment

- Antiplatelet therapy
- Control risk factors (e.g. hypertension, blood glucose)
- Vasodilators for symptomatic relief?



- Pain in calf, thigh, or buttock
- Occurs after consistent level of exercise
- Resolves with rest
- Aching, cramping sensation
- Benign condition
- 3% to 15% amputation rate over 3 years  
(depends on tobacco use)

- **Dull, aching pain of foot or toes**
- **Relieved by dependency, worsened by supine position**
- **May have paresthesia and pallor**
- **Demands prompt attention**
- **Does not lead to limb loss in 100%**






- **Pulselessness**
- **Pallor**
- **Pain**
- **Paralysis**
- **Paresthesia (or anesthesia)**
- **Demands immediate attention**




- **Decreased pulses**
- **Bruits (carotid, femoral, abdominal)**
- **Hair loss, muscle atrophy**
- **Atrophic, shiny skin**
- **Ulceration/gangrene (toes or foot)**
- **Dependent rubor**

Low Flow: rest



High Flow: exercise



Increased flow leads to greater energy loss across stenosis and hence greater pressure drop



- **Neuropathy**
- **Impaired immune function**
- **Greater prevalence of arterial disease**
- **Impaired inflammation**


- 
- **Segmental demyelination: distal > proximal**
  - **Paresthesia, loss of touch, vibration, temperature**
  - **“Stocking” distribution**
  - **Affects motor and autonomic nerves**

- **Weakening of intrinsic foot muscles**
- **Pes Cavus deformity, "Rocker-bottom foot"**
- **Hammer toe, extensor subluxation**
- **Maldistribution of weight over plantar surface**

# DIABETIC NEUROPATHY



Subluxed  
tarsal bone



Hammer Toe

Pes Cavus deformity





- **Poorly fitted shoes**
- **Foreign body in shoe**
- **Unrecognized trauma, burn**
- **Injudicious pedicure**
- **Problems compounded in elderly population with poor vision**



- **Digital or foot gangrene**
- **Necrosis with trivial injury or infection**
- **Neglected ulcers and infection can rapidly progress**



- Careful examination
- Signs of toxicity
- Fever, leukocytosis
- Hyperglycemia most sensitive indicator
- Frequent delay in diagnosis
- Minimal pain and inflammation
- Casual observer can easily miss deep abscess



- **Careful assessment by vascular surgeon**
- **Aggressive manipulation, probing**
  - **unroof eschars, bullae**
- **Radiologic assessment**
  - **soft tissue swelling, osteomyelitis, tissue gas**
- **Aggressive drainage and debridement**
- **Broad spectrum antibiotics**

# DIABETIC FOOT SEPSIS



# DIABETIC FOOT SEPSIS



VASCULAR HEALTH  
CLINICS



# DIABETIC FOOT SEPSIS



# DIABETIC FOOT SEPSIS





# DIABETIC UCLER WITH ISCHEMIA



VASCULAR HEALTH  
CLINICS



# DIABETIC UCLER WITH ISCHEMIA



VASCULAR HEALTH  
CLINICS



# DIABETIC ULCER WITH ISCHEMIA



VASCULAR HEALTH  
CLINICS



# DIABETIC ULCER WITH ISCHEMIA



# WET GANGRENE



VASCULAR HEALTH  
CLINICS



# WET GANGRENE



VASCULAR HEALTH  
CLINICS





- **Segmental pressures**
- **Pulse volume recording**
- **Duplex ultrasound**
- **Magnetic Resonance Angiography (MRA)**
- **Contrast Angiography**
- **Spiral CT**




- Insonate best pulse at ankle/foot level
- DP, PT, Peroneal
- Cuff inflation until systolic flow disappears
- Slowly release until flow detected
- Repeat at all levels



# SEGMENTAL LIMB PRESSURES



# SEGMENTAL LIMB PRESSURES



## Limitations of SLP measurements include:

- **Nondetection of isolated moderate stenoses (usually iliac) that produce little or no pressure gradient at rest**
- **Falsely elevated pressures in patients with diabetes calcified, incompressible arteries**
- **The inability to differentiate between arterial stenosis and occlusion**

## Ankle Brachial Index (ABI)

- Doppler systolic occlusion pressure at ankle
- Quantifies arterial obstruction
- Falsely elevated with calcified arteries (diabetics, dialysis patients)

# SEGMENTAL LIMB PRESSURES



VASCULAR HEALTH  
CLINICS




# ANKLE BRACHIAL INDEX

ABI	Symptoms
> 0.92	Normal
0.5 - 0.9	Claudication
< 0.4	Rest Pain
< 0.4	Tissue loss



- **Diabetes, renal failure results in incompressible tibial arteries ( $\geq 250$  mmHg) or ABI  $> 1.40$**
- **Toe pressures provides an accurate measurement of distal limb systolic pressures in vessels that do not typically become noncompressible**
- **A special small occlusion cuff is used proximally on the first or second toe**

- Measures changes in pressure reflecting arterial pulsatility
- Aid in localizing significant occlusive lesions
- Not affected by calcified vessels as the ABI



Healthy



Mild Arterial Disease




Moderate Arterial Disease



Severe Arterial Disease



# PULSE VOLUME RECORDING (PVR)



In the presence of arterial disease, the slope of the waveforms flattens, the pulse width widens, and the dicrotic notch is lost

# CHARACTERISTICS OF ARTERIAL IMAGING



Modality	Availability	Relative risk and complications	Strengths	Weaknesses	Contraindications
X-ray contrast angiography	Widespread	High risk Access site complications Contrast nephropathy Radiation exposure	'Established modality'	2D images Limited planes Imaging pedal vessels and collaterals in the setting of occlusion requires prolonged imaging and substantial radiation	Renal insufficiency Contrast allergy
MDCTA	Moderate	Moderate risk Contrast nephropathy Radiation exposure	Rapid imaging Sub-millimeter voxel resolution 3D volumetric information from axial slices Plaque morphology	Calcium causes 'blooming artifact' Stented segments difficult to visualize	Renal insufficiency Contrast allergy

# CHARACTERISTICS OF ARTERIAL IMAGING



Modality	Availability	Relative risk and complications	Strengths	Weaknesses	Contraindications
MRA	Moderate	None	True 3D imaging modality; infinite planes and orientations can be constructed Plaque morphology from proximal segments with additional sequences Calcium does not cause artifact	Stents cause artifact but alloys such as nitinol produce minimal artifact	Intracranial devices, spinal stimulators, pace-makers, cochlear implants and intracranial clips and shunts are absolute contraindications
Duplex	Widespread	None	Hemodynamic information	Operator-dependent and time-consuming to image both lower extremities Calcified segments are difficult to assess	None



## Endovascular

- Revascularization (angioplasty)
- Stent placement


## Surgical

- Endarterectomy
- Peripheral bypass graft
- Amputation


# RESULTS OF ARTERIAL RECONSTRUCTION




VASCULAR HEALTH  
CLINICS



**Aorto-Bifemoral  
Bypass**



**Femoral-Popliteal  
Bypass**




**Femoro-Femoral  
Crossover**

# RESULTS OF ARTERIAL RECONSTRUCTION




VASCULAR HEALTH  
CLINICS



# RESULTS OF ARTERIAL RECONSTRUCTION



VASCULAR HEALTH  
CLINICS




# RESULTS OF ARTERIAL RECONSTRUCTION

---



VASCULAR HEALTH  
CLINICS







# RESULTS OF ARTERIAL RECONSTRUCTION



VASCULAR HEALTH  
CLINICS




**BEFORE**

**AFTER**

# RESULTS OF ARTERIAL RECONSTRUCTION



VASCULAR HEALTH  
CLINICS



**BEFORE**




**AFTER**

# RESULTS OF ARTERIAL RECONSTRUCTION




VASCULAR HEALTH  
CLINICS




**BEFORE**

**AFTER**

# WET GANGRENE




# WET GANGRENE



# WET GANGRENE



VASCULAR HEALTH  
CLINICS



# WET GANGRENE



# WET GANGRENE



VASCULAR HEALTH  
CLINICS





# 37 YO DM WITH ESRD



VASCULAR HEALTH  
CLINICS



# 37 YO DM WITH ESRD



VASCULAR HEALTH  
CLINICS




# 37 YO DM WITH ESRD



VASCULAR HEALTH  
CLINICS



# 37 YO DM WITH ESRD



# 37 YO DM WITH ESRD



VASCULAR HEALTH  
CLINICS



# 37 YO DM WITH ESRD




VASCULAR HEALTH  
CLINICS





**To prevent a delay in treatment early vascular consultation and revascularization important as >85% of amputations may be prevented by early detection and appropriate treatment**











## CAROTID DISEASE


# CAROTID DISEASE




# CAROTID DISEASE



# CAROTID DISEASE



# CAROTID DISEASE




# CAROTID DISEASE

---



VASCULAR HEALTH  
CLINICS



## Symptomatic disease

- NASCET 1991, 1998
- VAST 1991
- ECST 1991

## Asymptomatic

- VAAT 1993
- ACAS 1995
- ACST 1995

# NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL (NASCET)

---



VASCULAR HEALTH  
CLINICS

- 50 centers in US and Canada
- Stratified patients into 30-69% and 70-99% stenosis

## Eligibility:

- TIAs or minor strokes within 3 mo. of entry into study



# NASCET: 70-99% 2-YEAR RESULTS



	Medical Rx Alone	Surgical Rx (+BMM)	P Value
Ipsilateral stroke	61/331 (26%*)	26/328 (9%*)	<0.001
Any stroke	64/331 (27.6%*)	34/328 (12.6%*)	<0.001
Any stroke or death	73/331 (32.3%*)	41/328 (15.8%*)	<0.001

\* Kaplan-Meier Estimate

# NASCET: 50-69% 2-YEAR RESULTS



	Medical Rx Alone	Surgical Rx (+BMM)	P Value
Ipsilateral stroke	80/428 (22.2%*)	57/430 (15.7%*)	0.045
Any stroke	113/428 (32.3%*)	85/430 (23.9%*)	0.026
Any stroke or death	156/428 (43.3%*)	120/430 (33.2%*)	0.005

\* Kaplan-Meier Estimate

# NASCET: <50% 2-YEAR RESULTS



	Medical Rx Alone	Surgical Rx (+BMM)	P Value
Ipsilateral stroke	110/690 (18.7%*)	89/678 (14.9%*)	0.16
Any stroke	151/690 (26.2%*)	148/678 (25.7%*)	0.88
Any stroke or death	209/690 (37.0%*)	208(678) (36.2%*)	0.97

\* Kaplan-Meier Estimate



- 
- 10 yr period, 2518 patients with CVAs, TIAs or retinal infarctions were randomized to medical vs. surgical + BMM treatment with 3 yrs. follow up
  - 80 medical centers in 14 countries
  - Medical treatment left up to discretion of physician
  - 6mo interval of qualifying event (vs 3mo in NASCET)

# ECST: >70% 2-YEAR RESULTS



	Medical Rx Alone	Surgical Rx (+BMM)	P Value
Ipsilateral stroke	16.8%	2.8%	<0.0001
Disabling or fatal stroke	11%	6%	<0.05
Any stroke or death	21.9%	12.3%	<0.01

# ASYMPTOMATIC CAROTID ATHEROSCLEROSIS TRIAL (ACAS)

---



VASCULAR HEALTH  
CLINICS

- **1662 men and women with asymptomatic  $\geq 60\%$  stenosis were randomized to best medical therapy vs. surgery plus BMM**

# NASCET: >60% 3-YEAR RESULTS



	Medical Rx Alone	Surgical Rx (+BMM)	P Value
Ipsilateral stroke  (+periopera tive death/strok e)	92/834  (11%*)	42/825  (5.1%*)	<b>0.006</b>
Any stroke or death	266/834  (31.9%*)	211/825  (25.6%*)	0.08



- 
- **Early recurrent stenosis**
  - **Hostile neck (radiation, radical neck dissection, tracheostomy, infection)**
  - **Surgically inaccessible lesion**
  - **Fibromuscular dysplasia**
  - **High medical risk (hard to define)**
  - **In setting of approved RCT (Not covered by CMS for asymptomatic disease)**





- **Stenosis  $\geq 50\%$** 
  - **CEA + BMM**
- **Stenosis  $\geq 50\%$  and high perioperative risk**
  - **CAS (as potential alternative)**
- **Stenosis  $< 50\%$** 
  - **BMM**
- **CEA within 2 weeks of symptoms**



- **Stenosis  $\geq$  60% and low risk**
  - **CEA + BMM**
- **Stenosis  $<$  60%**
  - **BMM**
- **Stenosis  $\geq$  80% and high anatomic risk for CEA**
  - **CAS (exceptions)**

**THANK YOU**

---



**VASCULAR HEALTH**  
CLINICS

**THANK YOU**